Home › Glioblastoma › California › Sacramento
Glioblastoma clinical trials in Sacramento, CA
4 studies for Glioblastoma are looking for participants at sites in and around Sacramento (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
RecruitingPhase 1/2
- University of California Davis Comprehensive Cancer Center, Sacramento
Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
RecruitingPhase 1
- University of California Davis Comprehensive Cancer Center, Sacramento
Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma
RecruitingPhase 3
- University of California Davis Comprehensive Cancer Center, Sacramento
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
RecruitingPhase 1
- University of California Davis Comprehensive Cancer Center, Sacramento
Glioblastoma trials in other cities
- New York City, NY30 studies
- Boston, MA28 studies
- Houston, TX26 studies
- Los Angeles, CA24 studies
- Durham, NC20 studies
- San Francisco, CA17 studies
- Chicago, IL15 studies
- Washington, DC15 studies
- Columbus, OH14 studies
- Miami, FL14 studies
- Rochester, MN13 studies
- Jacksonville, FL13 studies
Other studies in Sacramento
- Non-Small Cell Lung Cancer29 studies
- Lung Cancer22 studies
- Breast Cancer20 studies
- Prostate Cancer19 studies
- Metastatic Cancer16 studies
- Acute Myeloid Leukemia12 studies
- Heart Failure12 studies
- Pancreatic Cancer12 studies
- Cancer (all types)11 studies
- Colon Cancer11 studies
- Bladder Cancer10 studies
- Colorectal Cancer10 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.